Drugs / anti-CD7 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05290155 | May 2022 → Aug 2024 | T lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma +1 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD7 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05290155 ↗ |
| Modality | Cell therapy | “anti-CD7 CAR-T cells” NCT05290155 ↗ |
| Target | CD7 | “CAR T cell treatment targeting CD7” NCT05290155 ↗ |